Form ABS-EE Hyundai Auto Receivables For: Aug 31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM FOR SUBMISSION OF ELECTRONIC EXHIBITS FOR

 

ASSET-BACKED SECURITIES

 

Commission File Number of the issuing entity: 333-229037-05

 

Central Index Key Number of the issuing entity: 0001826501

 

Hyundai Auto Receivables Trust 2020-C

(Exact name of issuing entity as specified in its charter)

 

Commission File Number of the depositor: 333-229037

 

Central Index Key Number of the depositor: 0001260125

 

Hyundai ABS Funding, LLC

(Exact name of depositor as specified in its charter)

 

Central Index Key Number of sponsor (if applicable): 0001541028

 

Hyundai Capital America
(Exact name of sponsor as specified in its charter)

 

Weni Gieseking
(949) 732-2974
(Name and telephone number, including area code, of the person to contact in connection with this filing)

 

INFORMATION TO BE INCLUDED WITH THIS FORM

 

Item 1. File an Asset Data File in accordance with Exhibit 601(b)(102) (17 CFR 229.601(b)(102)).

 

Item 2. File an Asset Related Document in accordance with Exhibit 601(b)(103) (17 CFR 229.601(b)(103)).

 

 

 

EXHIBIT INDEX 

 

Exhibit Index
Exhibit		Document Description
102		Asset Data File
103		Asset Related Document (Additional Explanatory Disclosure)

 

 

SIGNATURES

 

The depositor has duly caused this Form to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Hyundai ABS Funding, LLC
	(Depositor)
Date:  September 21, 2023	By:	/s/ Charley Changmin Yoon
		Name: Charley Changmin Yoon
		Title: President and Secretary

 

 

ATTACHMENTS / EXHIBITS

EX-102

EX-103

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual
• Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E
• Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress